论文部分内容阅读
应用KY Chiu改良胶银技术和ABC法对60例大肠癌手术根治术标本进行AgNOR定量和CEA标记及与肠外转移关系的研究。结果表明:肠外转移组和无转移组AgNOR数量X±SD分别为15.24±4.83和10.58±2.25,相互比较t=5.3742,P<0.01,有非常显著意义。证明转移组癌细胞较无转移组癌细胞分化低,增殖快,恶性程度高和侵袭性强的特征。CEA标记结果显示:在阴、阳性分布上,两组之间无显著性差异(P>0.5),说明癌细胞合成产生CEA在两组之间不存在产生与否的问题,而只存在产生多与少的差异。在CEA阳性标记的强度分布上,转移组强阳性(卅)占72％,无转移组强阳性占18％,两组比较X~2=13.74,P<0.01,差异有非常显著性,表明转移组癌细胞内CEA含量高,其生物学行为较恶,有扩散转移倾向。联合应用AgNOR定量和CEA标记,更能全面反映大肠癌的生物学行为,可望作为客观参数。两者合用,起着互补作用,对估价预后更有意义。
The use of KY Chiu modified plastic silver technology and ABC method 60 cases of colorectal cancer surgery radical specimens AgNOR quantification and CEA markers and its relationship with extraintestinal metastasis. The results showed that the number of AgNOR X±SD was 15.24±4.83 and 10.58±2.25 in the parenteral metastasis group and non-metastasis group, respectively, and t=5.3742, P<0.01, which was very significant. It was proved that the cancer cells in the metastatic group had lower differentiation, faster proliferation, higher degree of malignancy and stronger invasiveness than the cancer cells without metastasis. CEA marker results showed that there was no significant difference between the two groups in the negative and positive distributions (P>0.5), indicating that the synthesis of CEA produced by cancer cells did not occur or not between the two groups. Difference with less. In the intensity distribution of CEA positive markers, the strong positive group (卅) accounted for 72% in the metastatic group and 18% in the non-metastasis group. The difference between the two groups was X~2=13.74, P<0.01, and the difference was very significant, indicating that the metastasis was significant. The content of CEA in the cancer cells in the group is high, its biological behavior is relatively evil, and there is a tendency of diffusion and metastasis. The combined application of AgNOR quantification and CEA markers can fully reflect the biological behavior of colorectal cancer, and can be used as an objective parameter. The combination of the two plays a complementary role and makes more sense in evaluating the prognosis.